Journal of Radiation Oncology

, Volume 3, Issue 2, pp 167–177

Prognostic significance of blood transfusion and anaemia on survival in stage IIIA/B/C and IVA oesophageal cancers treated with chemoradiotherapy

  • Jeffrey Tuan
  • Tam Cam Ha
  • Summer Pan
  • Maria Hawkins
  • Diana Tait
Original Research Article
  • 178 Downloads

Abstract

Objective

To evaluate the prognostic effect of blood transfusion (BT) on survival outcomes in patients with stage IIIA/B/C and IVA oesophageal cancers treated with induction chemotherapy and chemoradiotherapy (C → CRT).

Methods

The medical records of patients with oesophageal cancer treated with C → CRT at the Royal Marsden Hospital, U.K. between 2000 and 2007 were identified and reviewed retrospectively. Patients had weekly haemoglobin measurements and received BT to maintain haemoglobin at the level of 12 g/dL and above as per the institutional policy. Overall survival (OS), progression-free survival (PFS) and locoregional recurrence-free survival (LRFS) were estimated by the Kaplan-Meier method. Cox proportional hazards regression models were used to determine the effect of anaemic and transfusion status on survival outcomes after adjusting for selected prognostic characteristics.

Results

Among 151 stage IIIA/B/C and IVA patients, the two-year rates for OS (53 and 53 vs. 27 %), PFS (36 and 29 vs. 22 %) and LRFS (57 and 59 vs. 43 %) were higher in those who were not anaemic and those who were anaemic with transfusion vs. those who were anaemic without transfusion, respectively. At multivariate analysis, anaemic patients who received blood transfusion had significantly lower risk of death (hazard ratios (HR) = 0.41, 95 % CI 0.23–0.74, p = 0.003), progression (HR = 0.46, 95 % CI 0.25–0.84, p = 0.009) and locoregional relapse (HR = 0.38, 95 % CI 0.16–0.89, p = 0.025) vs. those who did not.

Conclusion

With these current data, there was a significant benefit of BT in stage IIIA/B/C and IVA oesophageal cancers treated with chemoradiation.

Keywords

Blood transfusion Anaemia Hypoxia Oesophageal cancer Chemoradiation 

Supplementary material

13566_2014_145_MOESM1_ESM.docx (4.1 mb)
ESM 1(DOCX 4239 kb)

References

  1. 1.
    UK CR. Cancer incidence-UK statistics. In Edition 2012Google Scholar
  2. 2.
    Statistics OfN. Cancer statistics registrations: registrations of cancer diagnosed in 2007, England. In National Statistics, Edition no.38. London.: 2012Google Scholar
  3. 3.
    Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; CD002092Google Scholar
  4. 4.
    Vogelzang NJ, Breitbart W, Cella D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol 34:4–12PubMedGoogle Scholar
  5. 5.
    Polee MB, Hop WC, Kok TC et al (2003) Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 89:2045–2050PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA 281:1623–1627PubMedCrossRefGoogle Scholar
  7. 7.
    Crosby TD, Brewster AE, Borley A et al (2004) Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 90:70–75PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Lind M, Vernon C, Cruickshank D et al (2002) The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 86:1243–1249PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Vaupel P, Mayer A (2005) Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 12:5–10PubMedCrossRefGoogle Scholar
  10. 10.
    Harrison LB, Chadha M, Hill RJ et al (2002) Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7:492–508PubMedCrossRefGoogle Scholar
  11. 11.
    Gleeson C, Spencer D (1995) Blood transfusion and its benefits in palliative care. Palliat Med 9:307–313PubMedCrossRefGoogle Scholar
  12. 12.
    Frommhold H, Guttenberger R, Henke M (1998) The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol 174(Suppl 4):31–34PubMedGoogle Scholar
  13. 13.
    Bush RS (1986) The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 12:2047–2050PubMedCrossRefGoogle Scholar
  14. 14.
    Dubray B, Mosseri V, Brunin F et al (1996) Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 201:553–558PubMedGoogle Scholar
  15. 15.
    Yi Y, Li B, Sun H et al. Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Tumour Biol 31: 333–340Google Scholar
  16. 16.
    Rades D, Schild SE, Bahrehmand R et al (2005) Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels. Cancer 103:1740–1746PubMedCrossRefGoogle Scholar
  17. 17.
    Rades D, Lang S, Schild SE, Alberti W (2006) Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer. Clin Oncol (R Coll Radiol) 18:139–144CrossRefGoogle Scholar
  18. 18.
    Rades D, Tribius S, Yekebas EF et al (2006) Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study. Int J Radiat Oncol Biol Phys 65:459–465PubMedCrossRefGoogle Scholar
  19. 19.
    Valencia Julve J, Alonso Orduna V, Esco Baron R et al (2006) Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Transl Oncol 8:22–30PubMedCrossRefGoogle Scholar
  20. 20.
    Littlewood TJ (2001) The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 28:49–53PubMedCrossRefGoogle Scholar
  21. 21.
    Kader AS, Lim JT, Berthelet E et al (2007) Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol 30:492–497PubMedCrossRefGoogle Scholar
  22. 22.
    Rades D, Stoehr M, Kazic N et al (2008) Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. Int J Radiat Oncol Biol Phys 70:1108–1114PubMedCrossRefGoogle Scholar
  23. 23.
    Vaupel P, Thews O, Hoeckel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243–259PubMedCrossRefGoogle Scholar
  24. 24.
    DeMaeyer EM. Preventing and controlling iron deficiency anaemia through primary health care : a guide for health administrators and programme managers. World Health Organization 1989Google Scholar
  25. 25.
    Bhide SA, Ahmed M, Rengarajan V et al (2009) Anemia during sequential induction chemotherapy and chemoradiation for head and neck cancer: the impact of blood transfusion on treatment outcome. Int J Radiat Oncol Biol Phys 73:391–398PubMedCrossRefGoogle Scholar
  26. 26.
    Molls M, Vaupel P, Brown JM (1998) Blood perfusion and microenvironment of human tumors: implications for clinical radiooncology. Springer, LondonGoogle Scholar
  27. 27.
    Kelleher DK, Mattheinsen U, Thews O, Vaupel P (1996) Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 56:4728–4734PubMedGoogle Scholar
  28. 28.
    Hockel M, Schlenger K, Aral B et al (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509–4515PubMedGoogle Scholar
  29. 29.
    Brizel DM, Sibley GS, Prosnitz LR et al (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285–289PubMedCrossRefGoogle Scholar
  30. 30.
    Grogan M, Thomas GM, Melamed I et al (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86:1528–1536PubMedCrossRefGoogle Scholar
  31. 31.
    Kapp KS, Poschauko J, Geyer E et al (2002) Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 54:58–66PubMedCrossRefGoogle Scholar
  32. 32.
    NCCN. Cancer- and chemotherapy-induced anaemia. In NCCN Clinical Practice Guidelines in Oncology, Edition 2010Google Scholar
  33. 33.
    Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616–1634PubMedCrossRefGoogle Scholar
  34. 34.
    Langendijk H, de Jong J, Wanders R et al (2003) The importance of pre-treatment haemoglobin level in inoperable non-small cell lung carcinoma treated with radical radiotherapy. Radiother Oncol 67:321–325PubMedCrossRefGoogle Scholar
  35. 35.
    Overgaard J, Hansen HS, Overgaard M et al (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5–85. Radiother Oncol 46:135–146PubMedCrossRefGoogle Scholar
  36. 36.
    Girinski T, Pejovic-Lenfant MH, Bourhis J et al (1989) Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 16:37–42PubMedCrossRefGoogle Scholar
  37. 37.
    Browman GP, Wong G, Hodson I et al (1993) Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 328:159–163PubMedCrossRefGoogle Scholar
  38. 38.
    Overgaard J, Horsman MR (1996) Modification of hypoxia-induced radioresistance in tumors by the Use of oxygen and sensitizers. Semin Radiat Oncol 6:10–21PubMedCrossRefGoogle Scholar
  39. 39.
    Hoff CM, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma—a prospective study. Radiother Oncol 103: 38–44Google Scholar
  40. 40.
    Zenda S, Hironaka S, Boku N et al (2008) Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Dis Esophagus 21:195–200PubMedCrossRefGoogle Scholar
  41. 41.
    Zhao KL, Liu G, Jiang GL et al (2006) Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy—a secondary analysis of three consecutive clinical phase III trials. Clin Oncol (R Coll Radiol) 18:621–627CrossRefGoogle Scholar
  42. 42.
    Moores DW, Piantadosi S, McKneally MF (1989) Effect of perioperative blood transfusion on outcome in patients with surgically resected lung cancer. Ann Thorac Surg 47:346–351PubMedCrossRefGoogle Scholar
  43. 43.
    Beynon J, Davies PW, Billings PJ et al (1989) Perioperative blood transfusion increases the risk of recurrence in colorectal cancer. Dis Colon Rectum 32:975–979PubMedCrossRefGoogle Scholar
  44. 44.
    Heiss MM, Mempel W, Delanoff C et al (1994) Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 12:1859–1867PubMedGoogle Scholar
  45. 45.
    Bush RS, Jenkin RD, Allt WE et al (1978) Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 3:302–306PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Jeffrey Tuan
    • 1
  • Tam Cam Ha
    • 2
  • Summer Pan
    • 2
  • Maria Hawkins
    • 3
  • Diana Tait
    • 4
  1. 1.Department of Radiation OncologyNational Cancer Centre SingaporeSingaporeSingapore
  2. 2.Division of Clinical Trials and Epidemiological SciencesNational Cancer Centre SingaporeSingaporeSingapore
  3. 3.Gray Institute for Radiation Oncology and BiologyOxfordUK
  4. 4.The Gastrointestinal UnitThe Royal Marsden HospitalLondonUK

Personalised recommendations